Skip to content

Change in AR at other companies

Incyte logo
IncyteINCY
$27.03M+187%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$700K-95.2%
Precigen logo
PrecigenPGEN
$22.49M+12,950%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$690K-143%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$12.89M-23.4%
CG Oncology logo
CG OncologyCGON
$587K

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$156.86B+21.7%
Enterprise value$171.41B+15.5%
P/E17×-3.4×
P/S5.3×+0.8×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's change in AR?
Gilead Sciences (GILD) reported change in AR of -$134M in Q1 2026.
How has Gilead Sciences's change in AR changed year-over-year?
Gilead Sciences's change in AR decreased by 69.6% year-over-year, from -$79M to -$134M.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.